Infection with a Brazilian isolate of Zika virus generates RIG‐I stimulatory RNA and the viral NS5 protein blocks type I IFN induction and signalling by Hertzog, Jonny et al.





Infection with a Brazilian isolate of Zika virus generates
RIG-I stimulatory RNA and the viral NS5 protein blocks
type I IFN induction and signaling
Jonny Hertzog∗1, Antonio Gregorio Dias Junior∗1, Rachel E. Rigby∗∗1,
Claire L. Donald∗∗2, Alice Mayer1, Erdinc Sezgin1, Chaojun Song4,
Boquan Jin4, Philip Hublitz3, Christian Eggeling1, Alain Kohl2
and Jan Rehwinkel1
1 Medical Research Council Human Immunology Unit, Medical Research Council Weatherall
Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
Oxford, UK
2 MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, UK
3 Genome Engineering Facility, Medical Research Council Weatherall Institute of Molecular
Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
4 Department of Immunology, The Fourth Military Medical University, Xi’an, PR China
Zika virus (ZIKV) is a major public health concern in the Americas. We report that ZIKV
infection and RNA extracted from ZIKV infected cells potently activated the induction of
type I interferons (IFNs). This effect was fully dependent on the mitochondrial antivi-
ral signaling protein (MAVS), implicating RIG-I-like receptors (RLRs) as upstream sensors
of viral RNA. Indeed, RIG-I and the related RNA sensor MDA5 contributed to type I IFN
induction in response to RNA from infected cells. We found that ZIKV NS5 from a recent
Brazilian isolate blocked type I IFN induction downstream of RLRs and also inhibited
type I IFN receptor (IFNAR) signaling. We defined the ZIKV NS5 nuclear localization sig-
nal and report that NS5 nuclear localization was not required for inhibition of signaling
downstream of IFNAR. Mechanistically, NS5 blocked IFNAR signaling by both leading
to reduced levels of STAT2 and by blocking phosphorylation of STAT1, two transcription
factors activated by type I IFNs. Taken together, our observations suggest that ZIKV infec-
tion induces a type I IFN response via RLRs and that ZIKV interferes with this response
by blocking signaling downstream of RLRs and IFNAR.
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Introduction
Viruses from the Flaviviridae family are enveloped and con-
tain a positive sense, single stranded RNA genome. This virus
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family includes many pathogens important to human health such
as hepatitis C virus and mosquito-borne dengue virus (DENV),
West Nile virus and Zika virus (ZIKV). ZIKV was initially described
in 1947 after isolation from monkeys living in the Zika forest in
Uganda [1, 2] but has only received notable attention since the
recent epidemic in Brazil and other parts of the Americas. ZIKV
can be categorized into viruses of the Asian and African lineage.
The 2015/2016 epidemic strain belongs to the Asian lineage and
shares a common ancestor with viruses causing outbreaks in Poly-
nesia in 2013/2014 [3, 4]. Infection is often asymptomatic or is
characterized by a self-limiting acute febrile illness, including mild
fever, maculopapular rash, arthralgia and conjunctivitis [5, 6]. In
adults, ZIKV infection has also been suggested to trigger Guillain-
Barre´ syndrome, a rapid-onset muscle weakness caused by an
autoimmune response [7]. ZIKV is most commonly transmitted by
Aedes mosquitoes; however, other routes of transmission include
sexual and maternal-fetal during pregnancy [8–10]. In the latter
case, in utero ZIKV infection may cause developmental defects
resulting in microcephaly [11]. Indeed, the recent epidemic coin-
cided and overlapped geographically with an increase in micro-
cephaly cases in newborns [3]. Moreover, ZIKV infects neural pro-
genitor cells and vertical transmission as well as fetal microcephaly
have been documented in mouse models [reviewed in: [7]].
Type I interferons (IFNs, including IFN-α and IFN-β) are
cytokines which coordinate many aspects of the mammalian
immune response to infectious microorganisms [12]. During viral
infections, type I IFNs are often crucial to successful immunity.
In the course of an infection, their expression is induced at the
transcriptional level in different types of cells. This occurs down-
stream of pathogen sensing by innate immune receptors [13, 14].
Sensors of virus presence often detect nucleic acids as molecu-
lar signatures of infection; for example, viral RNA or DNA are
potent triggers for type I IFN induction [13, 14]. These sensors
include toll-like receptors, which survey the endosomal compart-
ment, as well as cytosolic DNA receptors and RIG-I-like receptors
(RLRs) that are localized in the cytosol of cells [13, 14]. RLRs
are helicase proteins and include RIG-I and MDA5. RIG-I recog-
nizes viral RNAs that have uncapped 5’-ends marked by tri- or
diphosphate groups [15, 16]. Upon binding to viral or unusual
RNAs, RIG-I and MDA5 engage the adaptor protein MAVS. Signal-
ing downstream of MAVS activates transcription factors including
IRF3 andNF-κB,which then drive transcription of the genes encod-
ing type I IFNs and other antiviral genes [13, 14]. Once secreted,
type I IFNs bind to the dimeric type I IFN receptor (IFNAR) on
the same or other cells [12]. This results in activation of JAK1
and TYK2 kinases, which in turn phosphorylate and thereby acti-
vate STAT1 and STAT2. These transcription factors then form
a complex with IRF9 and induce the expression of hundreds of
interferon-stimulated genes (ISGs). The proteins encoded by ISGs
have a variety of direct and indirect antiviral effects [17].
ZIKV infection in cultured human cells and mice is controlled
by type I IFNs. For example, treatment of human skin fibroblasts or
A549 cells with IFN-α or IFN-β prior to infection diminishes ZIKV
replication [18, 19]. In vivo, ZIKV infection in mice is restricted
by type I IFNs. Virus replication, transmission and pathology are
exacerbated in animals lacking IFNAR, STAT2, MAVS or IRF tran-
scription factors and after treatment with an IFNAR blocking anti-
body [20–26]. Interestingly, in human monocyte-derived den-
dritic cells and skin fibroblasts, the addition of type I IFN after
or concomitantly with infection only modestly reduces ZIKV repli-
cation [18, 27], suggesting viral interference with the effects of
type I IFNs. Indeed, recent studies have reported that ZIKV NS5
proteins from African and French Polynesian isolates antagonize
IFNAR signaling by targeting STAT2 for degradation [19, 28].
However, NS5 and other ZIKV proteins from virus strains associ-
ated with the latest outbreak in Brazil have not yet been analyzed
in this context, which is important given that Zika virus isolates
differ significantly in in vivo and in vitro infection settings [29, 30].
Additionally, ZIKV infection has been suggested to prevent STAT1
and STAT2 phosphorylation [27].
We addressed the open question of how ZIKV is detected by
infected cells to induce type I IFNs. We report that ZIKV infected
cells accumulated RNA molecules that potently activated RIG-I in
a 5’-phosphate-dependent manner. MDA5-stimulatory RNAs were
also generated during infection, suggesting that ZIKV infection is
sensed by RLRs. Based on sequence information from a Brazilian
ZIKV isolate, we individually cloned all viral proteins into a mam-
malian expression vector. We demonstrate that NS5 from a Brazil-
ian 2015/2016 epidemic strain of ZIKV blocks type I IFN induction
mediated by RLRs and IFNAR signaling. The latter function of NS5
involved depleting STAT2 levels and preventing phosphorylation
of STAT1. Nuclear localization was not required for this function
of NS5. We propose a model in which ZIKV induces a type I IFN
response via cytosolic RNA sensors of the RLR family and antago-
nizes this response by blocking signaling downstream of RLRs and
IFNAR.
Results
ZIKV infection induces type I IFN and generates
RLR-stimulatory RNA
Infection of cells with RNA viruses often results in RIG-I- and/or
MDA5-dependent type I IFN production, and infected cells accu-
mulate RLR-stimulatory RNA molecules. Experimentally, this can
be tested by the extraction of RNA from infected cells followed by
transfection of reporter cells. For example, IAV infected cells accu-
mulate RIG-I-stimulatory RNAs and encephalomyocarditis virus
(EMCV) infection results in the generation of extractable RNAs
that activate MDA5 [31, 32]. This assay therefore faithfully pre-
dicts which RLRs are involved in detecting the virus in the infected
cell [33]. To test this in the context of ZIKV, we infected A549
cells with a ZIKV strain from Brazil (PE243, [34]) at a multiplic-
ity of infection (MOI) of 5 and extracted total RNA at different
time points post infection. We first tested whether a type I IFN
response was induced in this setting. Indeed, using RT-qPCR, we
found that IFNβ mRNA and several transcripts encoded by ISGs
were upregulated in ZIKV-infected A549 cells (Fig. 1A). Next, we
transfected RNA from A549 cells infected with ZIKV for 20 hours
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Figure 1. ZIKV infection generates RIG-I- and MDA5-stimulatory RNAs. (A) A549 cells were infected with ZIKV (MOI of 5) and total RNA was
extracted at the indicated time points. Expression levels of the indicated mRNAs were determined by RT-qPCR with samples assayed in technical
duplicates. Data were analyzed by the comparative Ct method. (B) A549 cells were infected with ZIKV (MOI of 5) and total RNA was extracted after
20 h (A549-ZIKV-RNA). 100 ng A549-ZIKV-RNA or RNA from uninfected cells (A549-RNA) was then transfected into the indicated p125HEK cells
(see Supporting Information Fig. 1). After 16 h, luciferase activity was determined. Data are shown as fold change compared to cells treated with
transfection reagent only. IVT-RNA, Neo1-99 in vitro transcribed RNA (RIG-I agonist); RLU, relative light unit. (C) IVT-RNA and A549-ZIKV-RNA were
treated with alkaline phosphatase (AP). Control samples were processed in parallel omitting AP (mock). These RNAs were then analyzed as in (B)
using wild-type p125HEK cells and four doses of RNA (0.05, 0.5, 5, and 50 ng). (D) The experiment shown in (B) was repeated using the indicated
p125HEK cell lines that were pre-treated with 3 U/ml IFN-A/D for 16 h and were then transfected with 50 ng of total RNA from uninfected cells
(A549-RNA) or with A549-ZIKV-RNA that was or was not treated with AP. (E) The experiment shown in (B) was repeated using A549-ZIKV-RNA
isolated at the indicated time points after infection. Panel (A) shows pooled data of two independent experiments (average and SEM (n = 4)).
Panel (B) is representative of three independent experiments (average and SD (n = 3)). Panels (C) and (D) are representative of two independent
experiments (average and SD (n = 3)). Panel (E) shows pooled data of two independent experiments (average and SEM (n = 6)).
(A549-ZIKV-RNA) into HEK293 cells stably expressing firefly
luciferase (F-Luc) under control of the IFNβ promoter (Supporting
Information Fig. S1A-C). A549-ZIKV-RNA induced expression of
the IFNβ reporter and the magnitude of the response was simi-
lar to that triggered by Neo1-99 in vitro transcribed (IVT) RNA,
a 5’-triphosphate containing RIG-I agonist [31] (Fig. 1B). RNA
from uninfected A549 cells did not induce the IFNβ promoter
in these settings (Fig. 1B). Next, we analyzed the response in
RIG-I or MAVS knockout reporter cells (Supporting Information
Fig. S1D-O). As expected, the response to IVT-RNA was fully
C© 2018 The Authors. European Journal of Immunology published by
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RIG-I- and MAVS-dependent (Fig. 1B). Induction of the IFNβ
reporter after A549-ZIKV-RNA transfection was strongly reduced
in RIG-I-deficient cells and was completely absent in MAVS knock-
out cells (Fig. 1B). To corroborate this finding, we treated A549-
ZIKV-RNA and IVT-RNA as a control with alkaline phosphatase
(AP), which removes the 5’-phosphates required for RIG-I acti-
vation [31]. Indeed, AP treatment abolished IFN induction in
response to IVT-RNA, and largely prevented the response to A549-
ZIKV-RNA (Fig. 1C). These results show that A549-ZIKV-RNA
contains RIG-I-stimulatory RNA molecules. To test whether the
remaining response to A549-ZIKV-RNA observed in RIG-I-deficient
cells or after AP treatment could be attributable to MDA5, we
included MDA5 knockout cells in the analysis (Supporting Infor-
mation Fig. 1). Indeed, the response to AP-treated A549-ZIKV-RNA
was MDA5-dependent (Fig. 1D). We also analyzed the kinetics
of RLR-stimulatory RNA accumulation in ZIKV-infected cells and
found this had occurred between 8 and 24 h post-infection (Fig.
1E), correlating with the time course of IFNβ and ISGmRNA induc-
tion in infected cells (Fig. 1A). This therefore suggests that viral
replication might be required to activate RLRs. Taken together,
these observations show that ZIKV infection results in the accu-
mulation of RIG-I- and MDA5-stimulatory RNAs.
We next asked whether RIG-I directly binds viral RNAs. We
employed an in vitro assay in which recombinant FLAG-tagged
RIG-I protein and total RNA from infected cells were mixed in a
test tube [16]. After incubation, RIG-I was immunoprecipitated
with α-FLAG antibodies and RNAs that co-purify with the protein
were extracted. These RNAs were then analyzed for their potential
to induce a response in our IFNβ promoter reporter cells and for
the presence of viral RNAs (Fig. 2A). Negative controls included
immunoprecipitation with non-specific control antibody and the
use of denatured RIG-I protein. Western blot analysis confirmed
that both native and denatured RIG-I were precipitated by α-FLAG
but not by control antibody (Fig. 2B, E and data not shown). As
RIG-I recognizes the RNA genome of IAV [31], we used total RNA
from HEK293T cells infected with this virus as a positive control.
As expected, native but not denatured RIG-I bound to RNAs that
stimulated reporter expression in a RIG-I-dependent manner (Fig.
2C and data not shown). RT-qPCR analysis confirmed that RNA
corresponding to the M segment of IAV was bound by native RIG-I
(Fig. 2D). Similarly, pulldown of native RIG-I mixed with A549-
ZIKV-RNA retained IFN-stimulatory RNAs (Fig. 2F). Moreover,
RT-qPCR using a probe corresponding to nucleotides 4930–5029
of the full length ZIKV RNA genome demonstrated an association
of ZIKV RNA with RIG-I (Fig. 2G). This finding is consistent with
the accumulation of RIG-I-stimulatory RNAs in ZIKV-infected cells
and shows that RIG-I is capable of recognizing ZIKV RNAs.
Construction of ZIKV Brazil protein expression vectors
To further study the interaction between ZIKV and the type I IFN
system, we prepared a library of expression constructs for indi-
vidual ZIKV proteins. Importantly, we based our analysis on the
sequence of ZIKV strain Natal RGN, Brazil (KU527068) [11]. In
contrast, an earlier study used sequences derived from a viral
strain from French Polynesia [19]. In brief, coding sequences
were assembled by gene synthesis, cloned into a gateway entry
vector and then shuttled into pcDNA3.2 for expression in mam-
malian cells with an C-terminal V5 tag. Our library included the
three structural proteins (C, prM, E), the seven non-structural
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5), as well as
several fusion proteins (NS2B-NS3, NS4A-2K, 2K-NS4B, NS4A-
2K-NS4B) (Fig. 3A). Following transient transfection of HEK293
cells, expression of ZIKV proteins was tested by Western blot using
an antibody against the V5 tag (Fig. 3B–D). C, NS1, NS3, NS4A,
NS4B, NS5 and 2K-NS4B constructs were expressed well and a
single band of the predicted molecular weight was detected (Fig.
3B). Other constructs were expressed at lower levels and for some
multiple bands were evident, which may reflect post-translational
modifications, protein degradation or aggregation (Fig. 3B, C). We
also constructed a vector expressing NS5 fused at its C-terminus to
enhanced yellow fluorescent protein (eYFP) for localization stud-
ies (Fig. 3D).
ZIKV NS5 inhibits the induction of type I IFN
downstream of RLRs
Given that ZIKV infection generates RNAs that activate the RLR
pathway (Figs. 1 and 2), we asked whether the virus encodes
an antagonist of RLR-driven type I IFN induction. To test this
idea, we transiently transfected HEK293 cells with ZIKV expres-
sion vectors.We included an IFNβ promoter F-Luc reporter plasmid
and, for normalization, a Renilla luciferase control plasmid in the
transfection mix. After overnight incubation, cells were stimulated
with RLR agonists and induction of the reporter was determined
(Fig. 4A). Empty vector and an expression plasmid for EMCV-L,
a known antagonist of IRF3 [35], served as negative and positive
controls, respectively. As expected, IFNβ promoter activation by
the synthetic RIG-I agonist IVT-RNA and by A549-ZIKV-RNA were
blunted by EMCV-L expression (Fig. 4B). Interestingly, ZIKA NS5
had similar inhibitory effects, while the other viral proteins had
no effect on expression of the IFNβ promoter reporter (Fig. 4B).
NS5 also blocked activation of the reporter by an MDA5 agonist,
VERO-EMCV-RNA [32] (Fig. 4C). These data indicate that ZIKV
NS5 is a viral inhibitor of type I IFN induction mediated by RLRs.
NS5 blocks type I interferon receptor signaling
We next investigated whether NS5 or other ZIKV proteins block
type I interferon receptor signaling. We recently described a sta-
ble reporter cell line that contains F-Luc under the control of
an interferon-stimulated response element (ISRE) [36]. Exposure
to type I IFN induces F-Luc expression in these cells. We tested
whether overexpression of ZIKV proteins blocks the induction of
the ISRE reporter gene. When ZIKV proteins were expressed indi-
vidually, only NS5 reduced F-Luc induction in response to recom-
binant type I IFN (Fig. 5A). Other ZIKV proteins did not reduce
C© 2018 The Authors. European Journal of Immunology published by
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Figure 2. RIG-I binds ZIKA RNA. (A)
Schematic of the experimental setup. Please
see results for detail. HEK293T-IAV-RNA
(panels B–D) andA549-ZIKV-RNA (E–G)were
used. (B, E) Input, unbound and bound sam-
ples were analyzed byWestern blot using α-
FLAG antibody. (C, F) RNAs extracted from
input, unbound and bound samples were
transfected into p125HEK cells (see Support-
ing Information Fig. 1). After 16 h, luciferase
activity was determined and set to 1 for
control samples treated with transfection
reagent alone. RLU, relative light unit. (D,
G) RNA samples from (C) and (F) were ana-
lyzed in technical duplicate by RT q-PCR
using the indicated probes. Relative viral
transcript abundance was analyzed by con-
verting Ct data to 2−Ct values. Panels (B) and
(E) are representative of three independent
experiments. Panels (C), (D), (F) and (G) show
pooled data from three independent exper-
iments (average and SEM (n = 6)).
the induction of the ISRE reporter (Fig. 5A). It is possible that dif-
ferent ZIKV proteins may act together to block IFNAR signaling;
hence, we repeated the experiment by co-transfecting groups of
five ZIKV expression plasmids arranged so that each ZIKV protein
was expressed with every other protein at least once. Any plas-
mid combination containing ZIKV NS5 blocked ISRE induction,
while combinations not including NS5 did not interfere with the
response to type I IFN (Fig. 5B). In line with this observation, we
found that combinations of three plasmids not including NS5 did
not block IFNAR signaling (Fig. 5C).
The effect of NS5 in the stable reporter cells used in Figs. 5A–C
was incomplete. This may be due to limited transfection efficiency
and responses from non-transfected cells contained in the well.
We therefore repeated the experiment by transient transfection
C© 2018 The Authors. European Journal of Immunology published by
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Figure 3. Cloning and expression of ZIKV proteins. (A) Expression constructs. The DNA sequence of the single ZIKV open reading frame encoding
all structural and non-structural proteins was derived from a sequenced ZIKV complete genome (GenBank accession KU527068; origin Brazil)
recovered from the brain of a microcephalic, aborted foetus. Segments encoding individual proteins were annotated using sequence alignment
with a reference genome (GenBank accession NC 012532.1). Expression constructs generated and used in this study are shown as double lines.
(B) HEK293 cells were transfected with plasmids expressing the indicated ZIKV proteins. Cell lysates were prepared 24 h after transfection and
protein expression was determined by Western blot using the indicated antibodies with GAPDH as loading control. MW, molecular weight. (C,
D) The experiment shown in panel (B) was repeated using HEK293T cells and the indicated plasmids. Data are representative of at least three
independent experiments.
of an ISRE-F-Luc reporter plasmid together with ZIKV expression
constructs and a constitutively expressed Renilla luciferase plas-
mid. In this setting, the response to recombinant type I IFN was
completely blocked by NS5 (Fig. 5D). NS4A weakly blocked ISRE
induction and all other ZIKV proteins failed to have an effect (Fig.
5D). N-terminally eYFP tagged NS5 also blocked ISRE induction
(Fig. 5E).
To test whether NS5 interferes with induction of endogenous
ISGs after exposure of cells to type I IFN, we measured the expres-
sion of DDX58 (encoding RIG-I), MX1, IFIT1 and IFI44 by RT-
qPCR. Expression of these ISG mRNAs was induced to different
levels after type I IFN treatment and this was blocked by the pres-
ence of NS5 (Fig. 6A). Similarly, RIG-I protein levels were induced
by type I IFN and this was prevented by NS5 expression (Fig. 6B).
Taken together, these data demonstrate that NS5 is the major
antagonist of IFNAR signaling and ISG induction encoded by a
ZIKV isolate from Brazil.
ZIKV NS5 depletes STAT2 levels and blocks STAT1
phosphorylation
Earlier work suggested that ZIKV NS5 targets STAT2 for degra-
dation [19, 28] and that ZIKV infection blocks STAT1 phosphory-
lation [27]. Therefore, we investigated the mechanism by which
NS5 interferes with IFNAR signaling and tested STAT1 and STAT2
expression and phosphorylation levels byWestern blot. NS5 bound
to STAT2 and STAT2 levels were reduced by NS5 suggesting that
NS5 may target STAT2 for degradation (Fig. 6C and S2). In con-
trast, STAT1 protein levels were unchanged inNS5 expressing cells
that were not treated with IFN (Fig. 6C). STAT1 is an ISG [17]
and, as expected, induction of STAT1 protein by IFN was blocked
by NS5 (Fig. 6C). Moreover, STAT1 phosphorylation was readily
detectable in control cells treated with type I IFN but was strongly
reduced in NS5 expressing cells (Fig. 6C). Analysis of the ratio of
total and phosphorylated STAT1 by densitometry showed that NS5
C© 2018 The Authors. European Journal of Immunology published by
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Figure 4. ZIKV NS5 blocks type I IFN induction by RLRs. (A) Schematic of the experimental setup. Please see results for detail. (B, C) HEK293
cells were transiently transfected with the indicated ZIKV plasmids, a plasmid encoding F-Luc under control of the IFNβ promoter and a plasmid
expressing Renilla luciferase (R-Luc) from the constitutive thymidine kinase (TK) promoter. Cells were transfected with RLR-stimulatory RNAs after
24 h as indicated. F-Luc and R-Luc activities in cell lysates were determined after an additional 24 h and the F-Luc / R-Luc ratio was set to 1 in cells
that received only transfection reagent at the RNA transfection step. Data are representative of three independent experiments (average and SD
(n = 3)).
expression prevented STAT1 phosphorylation (Fig. 6D) suggesting
that NS5 is the viral protein blocking STAT1 phosphorylation dur-
ing ZIKV infection [27]. Taken together, these data indicate that
NS5 blocks IFNAR signaling by multiple mechanisms, including
reduced STAT2 levels and inhibition of STAT1 phosphorylation.
NS5 nuclear localization is not required for inhibition
of IFNAR signaling
ZIKV NS5 is predominantly localized in the cell nucleus and binds
to importin α/β1 [28, 37–39]. NS5 has an N-terminal methyltrans-
ferase (MTase) domain and a C-terminal RNA polymerase domain,
which are separated by the interdomain region. In DENV NS5,
this region contains nuclear localization signals (NLSs) including
the aNLS element that is recognized by importin α/β1 [40, 41].
The DENV NS5 aNLS is characterized by two clusters of function-
ally essential basic residues [41], some of which are conserved in
ZIKV (Fig. 7A). To test if these residues are required for nuclear
localization of ZIKV NS5, we mutated both clusters individually
and together (Fig. 7A). We then expressed wild-type and mutant
NS5-eYFP fusion proteins in HEK293T cells and analyzed NS5
localization by fluorescence microscopy. As expected, wild-type
NS5 was found in the cell nucleus (Fig. 7B). Mutation of clus-
ter 1 (RQ to AA) or cluster 2 (KHK to AAA) did not change
this pattern, while mutation of both clusters together resulted
in redistribution of NS5 to the cytoplasm (Fig. 7B). This observa-
tion defines the RQ-KHK aNLS motif in ZIKV NS5 as a functional
bipartite NLS. Interestingly, we found that the NS5 NLS mutant
was capable of blocking ISRE induction and reducing STAT2 levels
(Fig. 7C, D).
The MTase activity of NS5 contributes to the formation of cap
structures on viral transcripts by guanine N-7 and ribose 2’-OH
methylation [42]. The E218A mutation in yellow fever virus NS5
disrupts ribose 2’-OH methylation [43]. To test if MTase activity,
in the absence of the canonical viral RNA substrate, is related to
the effects of NS5 on IFNAR signaling, we introduced the same
mutation into ZIKV NS5. However, overexpression of the E218A
C© 2018 The Authors. European Journal of Immunology published by
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Figure 5. ZIKV NS5 blocks type I IFN signaling. (A) Stable HEK293-ISRE-reporter cells were transfected with ZIKV plasmids as indicated and, 24 h
later, were treated or were not with 20U/ml IFN-A/D. Luciferase activity in cell lysates was determined 24 h after transfection and was set to 1 in
untreated cells that received empty vector. (B,C) The experiment shown in (A) was repeated using plasmid combinations as indicated on the left.
(D,E) HEK293T cells were transiently transfected with the indicated ZIKV plasmids, a plasmid encoding F-Luc under ISRE control and a plasmid
expressing Renilla luciferase (R-Luc) from the TK promoter. Cells were treated with IFN-A/D after 24 h as indicated. F-Luc and R-Luc activities in cell
lysates were determined after an additional 24 h and the F-Luc / R-Luc ratio was set to 1 in untreated cells that received empty vector. Panels (A),
(D), (E) are representative of three independent experiments (average and SD (n = 3)). Panels (B) and (C) show pooled data from three experiments
(average and SEM (n = 9)). (A), (D), (E): unpaired, two-tailed t-test as indicated. (B), (C): unpaired, two-tailed t-test vs empty vector. (*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001).
NS5 mutant in the absence of a viral substrate for methylation
neither impaired NS5-mediated inhibition of ISRE induction nor
STAT2 depletion (Fig. 7C, D). Comparison of the African MR-766
ZIKV isolate and Brazilian strains revealed two amino acid sub-
stitutions in NS5, M2634V in the MTase domain and M3392V in
the RNA polymerase domain [3]. We reverted these two valines at
position 2634 and 3392 in our NS5 construct to methionine to test
if these residues are involved in antagonism of IFNAR signaling.
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Figure 6. NS5 triggers STAT2 depletion and blocks STAT1 phosphorylation. (A) HEK293T cells were transfected with the indicated ZIKV plasmids
and either were or were not treated with 25U/ml of IFN-A/D. RNA was extracted after 24 h and expression levels of the indicated mRNAs were
determined by RT-qPCR with samples assayed in technical duplicate. Data were analyzed by the comparative Ct method and set to 1 for untreated
cells transfected with empty vector. (B,C) Cell lysates were prepared from HEK293T cells transfected with the indicated plasmids and treated with
IFN-A/D for 24 h. Expression of the indicated protein was determined by Western blot with β-actin as loading control. (D) Quantification of signals
in (C) using the image densitometry analysis tool of ImageJ. Panels (A) - (C) are representative of three independent experiments. Panel (A) shows
average and range (n = 2).
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Figure 7. Blockade of type I IFN signaling by NS5 does not require NS5 nuclear localisation. (A) The NS5 interdomain regions from different
flaviviruses were aligned and the area around the aNLS is shown. Residues involved in nuclear localization of DENV NS5 are highlighted in black.
The aNLS mutations studied in (B) are indicated in blue at the bottom. DENV: Dengue virus; YFV: yellow fever virus; WNV: West Nile virus; JEV:
Japanese encephalitis virus; YOKV: Yokose virus; SPOV: Spondweni virus; ZIKV: Zika virus – AF: Africa, MA: Malaysia, MI: Micronesia, AM: America.
(B) HEK293T cells were transfected with wild-type NS5-eYFP or NS5 NLSmutant constructs as shown in panel (A). After 24 h, live cells were imaged
with a confocal microscope. Nuclei were stained with the membrane permeable dye, NucBlueTM. Scale bar is 25 μm. (C, D) HEK293T cells were
transfected as in Fig. 5D using the indicated ZIKV plasmids and were treated with 25U/ml of IFN-A/D or IFNβ. 24 h after transfection, luciferase
activities were analyzed as in Fig. 5D (C) and cell lysates from untreated samples were analyzed byWestern blot with β-actin as loading control (D).
(E) HEK293T cells were transfected with ZIKV NS5-eYFP. After 24 h, the mobility of nuclear NS5 speckles was analyzed by fluorescence recovery
after photobleaching (FRAP). Representative snapshots of a cell nucleus expressing NS5-eYFP before, during and after bleaching of the speckle
indicated by the red circle are shown, indicating that fluorescence of NS5 recovered and that the protein was mobile and in a fluid environment.
Scale bar is 2 μm. (F) The intensity of NS5 speckles was normalized to 1 before photobleaching and was analyzed over time after photobleaching.
The fluorescence intensity in NS5 speckles dropped to 25% of the initial value and then recovered back to 75%. Panels (B)–(F) are representative
of at least three independent experiments. Panel C shows average and SD (n = 3). Panel (F) shows average of five speckles and SD.
However, this “NS5 African mutant” behaved like the parental
NS5 construct based on the Brazilian strain sequence (Fig. 7C and
D). Taken together, these data show that NS5 nuclear localization
was not required for blocking IFNAR signaling.
Our analysis of ZIKV NS5 localization showed that NS5 is
not uniformly distributed across the cell nucleus, but appears
to be enriched in dot-like structures (Fig. 7B). We investigated
the dynamics of these NS5 speckles using fluorescence recovery
after photobleaching (FRAP). NS5 speckles recovered at the site
of bleaching within about 1 min, suggesting that these structures
are highly dynamic and presumably “liquid” in nature [44] (Fig.
7E and F).
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Discussion
Innate immune responses play an important role in determining
the course of disease caused by virus infection. It is therefore
important to understand how such responses are initiated and
how viruses evade and antagonize them. Here, we studied this
question in the context of the emerging pathogen ZIKV, and show
that ZIKV infection generates RNA molecules that stimulate RIG-I
and MDA5. These sensors of virus invasion induce type I IFNs,
which activate an anti-viral gene expression program by signaling
through their receptor, IFNAR. We report that ZIKV antagonizes
RLR and IFNAR signaling by means of its NS5 protein, and inves-
tigate sequences and cellular location responsible.
Our results demonstrate that ZIKV infection results in the accu-
mulation of RIG-I stimulatory RNAs. RIG-I detects RNA molecules
bearing 5’-triphosphate groups [31]. NS5 is an RNA-dependent
RNA polymerase that replicates the genomes of viruses belong-
ing to the Flaviviridae family and employs a primer-independent
mechanism of initiation [45]. This results in the presence of
triphosphate groups derived from the initiating ribonucleoside
triphosphate at the 5’-ends of nascent viral RNAs, whichwe predict
activate RIG-I in ZIKV infected cells. Indeed, we report that RIG-I
could directly associate with ZIKV RNA and that phosphatase-
treatment renders RNA from ZIKV infected cells unable to stimu-
late RIG-I. It will be interesting to confirm this by infection experi-
ments in RIG-I-deficient cells and by RIG-I pulldowns from infected
cells.
Flaviviral replication complexes assemble on ER membranes
and reside in vesicles formed by membrane invaginations, also
known as replication factories [45]. How then, does RIG-I–-which
is localized in the cytosol-–gain access to newly replicated viral
RNAs? Analysis of ZIKV infected cells by electron microscopy
revealed pore-like openings connecting replication factories to the
cytosol [46]. It is conceivable that at least some nascent viral RNAs
escape through these pores and are then sensed by RIG-I. Indeed,
the RIG-I pathway is very sensitive and is triggered by less than 20
RNA molecules per cell [47]. Moreover, replication factories are
likely to be dynamic structures.
Interestingly, we find that ZIKV infection generates not only
RIG-I agonists but also MDA5-stimulatory RNAs. Dual activation
of RIG-I and MDA5 is consistent with the observation that IFN
induction downstream of both RIG-I and MDA5 is blocked by
sfRNA, a subgenomic, non-coding RNA expressed during ZIKV
infection [34]. Furthermore, infection with other members of
the Flaviviridae family, such as hepatitis C virus, activates both
RLRs [48]. Although the molecular properties of RNAs that acti-
vate MDA5 are not fully understood, it is clear that MDA5 acti-
vation, in contrast to RIG-I, does not require the presence of 5’-
triphosphates [13, 14]. NS5 in conjunction with NS3 caps flavivi-
ral RNAs by sequential triphosphatase, guanylyltransferase and
methyltransferase activities [45]. It is likely that capping is an
evasion strategy that allows viral RNAs to escape detection by
RIG-I and other factors such as IFIT proteins [15]. It is possible
that MDA5 detects mature ZIKV RNAs and thereby functions as a
backup if RIG-I activation is limited by capping.
Many viruses, including flaviviruses, encode inhibitors of the
type I IFN system [49–51]. Viral antagonists typically dampen but
do not completely shut-down the host response and block type
I IFN induction or repress IFNAR signaling. We found that ZIKV
NS5 acted at both of these levels and prevented RLR-driven type I
IFN induction as well as IFN-mediated ISG expression. The former
observation suggests that the reduced type I IFN response reported
in ZIKV infected cells transfected with synthetic RLR agonists [19,
27, 52] is due to NS5. The finding that type I IFN responses to both
RIG-I andMDA5 stimuli were blocked by NS5 further suggests that
NS5 acts at the level of the common adaptor MAVS or downstream
in the RLR signaling pathway. This is consistent with a recent
study suggesting that NS5 interacts with and blocks IRF3 [30].
Another possibility is that NS5 inhibits RLR signaling indirectly
by antagonizing ISG expression, as, in a feed-forward loop, both
RIG-I and MDA5 are encoded by ISGs. It will be interesting for
future studies to investigate the mechanism by which NS5 blocks
RLR signaling.
Recent work using African and French Polynesian ZIKV isolates
already demonstrated that ZIKV NS5 interferes with IFNAR sig-
naling by targeting STAT2 for proteasomal degradation [19, 28].
Here, we extend these findings in several ways. First, we show that
NS5 from a Brazilian ZIKV strain collected from an aborted, micro-
cephalic fetus blocks the response to type I IFN. This demonstrates
that IFNAR signaling is targeted by a ZIKV isolate derived from
the recent epidemic. Second, by using our expression constructs
for ZIKV proteins alone or in combination, we report that NS5 is
likely to be the only potent ZIKV antagonist of IFNAR signaling.
It is possible that other viral proteins make a small contribution
to blocking IFNAR signaling. For example, we found that NS4A
expression slightly dampens the response to type I IFN (Fig. 5D)
and Wu et al. as well as Xia et al. recently reported effects of sim-
ilar magnitude for NS2B-NS3 and other viral proteins [30, 53].
It is likely that this fine-tuning of the response depends on the
virus strain, kinetics and precise experimental setup, while it is
clear from our data and those of others [19, 28] that NS5 has
the most potent and lasting effect. Thirdly, we show that ZIKV
NS5 not only reduces STAT2 levels but also blocks STAT1 phos-
phorylation. This is consistent with a report studying the effects
of ZIKV infection in dendritic cells [27] and indicates that ZIKV
NS5 has evolved multiple strategies to counteract IFNAR signal-
ing [50, 51]. Fourthly, we define a NLS in ZIKV NS5. Earlier work
using the African MR-766 strain found that deletion of four amino
acids (KRKR), which overlap with the second half of the bipartite
RQ-KHK motif identified here (Fig. 7A), abrogates nuclear local-
ization of overexpressed NS5 [38]. In contrast, we found that the
KHK residues in NS5 from a Brazilian isolate were required, but
not sufficient, for nuclear localization of the protein, which also
required the RQ motif. These observations highlight differences
between ZIKV strains. Furthermore, we demonstrate that NS5
nuclear localization was not required for the inhibition of IFNAR
signaling. Future studies should address the molecular mechanism
by which NS5 targets STAT transcription factors. For example, it
will be interesting to identify the E3 ubiquitin ligase required for
STAT2 degradation.
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It will also be important to delineate the role of NS5 in the cell
nucleus. It has been suggested that nuclear NS5 from other fla-
viviruses blocks IL-8 induction [reviewed in: [54]]. Interestingly,
we found that NS5 is organized as speckles in the nucleus. Sev-
eral recent studies reported similar findings for overexpressed and
endogenous NS5 [28, 38, 39]. Using immunofluorescence with α-
PML antibody, we found that these structures do not correspond
to PML bodies (data not shown). Instead, it is possible that these
nuclear NS5 speckles correspond to sites of splicing, given that NS5
co-localizes with SC35, a cellular protein involved in pre-mRNA
splicing [38]. Indeed, DENV NS5 has been reported to bind to
components of the spliceosome and to modulate splicing of host
genes, including DDX58 (encoding RIG-I) [55]. We further report
that the molecules in these speckles were in constant exchange
with the surrounding NS5, which suggests that these compart-
ments are “liquid” in nature. This kind of liquid-liquid phase sep-
aration has been described for proteins forming membrane-less
compartments such as P granules, typically together with nucleic
acids or other proteins [56, 57]. This type of compartmentaliza-
tion plays a role in several processes such as RNA metabolism,
biogenesis of the ribosome, DNA damage response and signal
transduction [58]. Therefore, it will be an intriguing quest for the
future to elucidate the role of this compartmentalization in NS5
function.
Finally, it would be interesting to define mutations in NS5
that selectively disrupt its ability to block RLR or IFNAR signaling
while leaving intact its essential functions in the viral life cycle.
We predict that suchmutant viruses induce elevated IFN responses
and only replicate efficiently in cells deficient for components of
the type IFN system.
Taken together, we define the interplay between ZIKV and
the type I interferon system and identify three points of interac-
tion between the virus and cells: ZIKV infection generates stimuli
for the pattern-recognition receptors RIG-I and MDA5, and the
viral NS5 protein blocks the ensuing antiviral response by antag-
onizing RLR signaling and STAT transcription factors that are
involved in IFNAR signaling. It is likely that these host-pathogen




Cells were maintained in DMEM (Sigma Aldrich) supplemented
with 10% FCS (Sigma-Aldrich) and 2 mM L-Glutamine (Gibco) at
37°C and 5% CO2. 3C11 cells are HEK293 cells (originally from
Caetano Reis e Sousa, The Francis Crick Institute, London, UK)
stably transduced with an ISRE-Luc reporter construct [36]. A549
cells were obtained from R. E. Randall, University of St Andrews,
UK.
Plasmids
To generate p125-GreenFire, the human IFNβ promoter region
was amplified from the p125-Luc plasmid [59] and cloned into the
pGreenFire1-ISRE lentiviral reporter system (System Biosciences,
TR016PA-P) using EcoRI and BamHI restriction enzymes to excise
the ISRE elements and theminimal CMV promoter. The puromycin
N-acetyl-transferase gene was replaced by the blasticidin-S deam-
inase gene from the pLenti6.3/V5-DESTTM Gateway R© Vector
(Invitrogen) using the restriction enzyme KpnI.
Plasmids used for luciferase reporter assays were p125-Luc
[59], ISG54-Luc (Clontech), and pRL-TK (Promega).
A DNA sequence of the single ZIKV open reading frame encod-
ing for all structural and non-structural proteins was derived
from a sequenced ZIKV complete genome (GenBank accession
KU527068) recovered from the brain of a microcephalic aborted
foetus [11]. The genome was annotated for sequence segments
encoding individual proteins using sequence alignment with an
annotated reference genome (GenBank accession NC 012532.1)
[60]. DNA fragments encoding for the Capsid, Envelope, and pr-
Membrane proteins as well as the non-structural proteins NS2A,
NS2B, NS3, NS4A-2K, and NS4B were obtained by gene synthe-
sis (GeneArt String linear DNA fragments; Thermo Fisher Sci-
entific) after addition of a start codon (AUG) to the 5’ end of
DNA sequences. Fragments were cloned into the pCR8/GW/TOPO
Gateway entry vector (Invitrogen). After sequence integrity was
verified via sequencing, inserts were Gateway-cloned into the
pcDNA3.2/V5-DEST vector (Invitrogen) using the Gateway LR
Clonase II Plus Enzyme Mix (Invitrogen). Fragments encoding
the non-structural proteins NS1 and NS5 were generated by gene
synthesis into the pDONR221 Gateway donor vector (GeneArt
Gene, Thermo Fischer Scientific) and Gateway-cloned into the
pcDNA3.2/V5-DEST vector. DNA constructs encoding the other
ZIKV proteins utilized in this project (NS4A, 2K-NS4B, NS4A-
2K-NS4B, NS2B-NS3, NS5-eYFP) were created by (Overlap)-PCR
from existing ZIKV protein encoding plasmids using Phusion High
Fidelity DNA Polymerase (New England Biolabs). NS5 mutants
were created by mutagenesis PCR and confirmed by sequencing.
ZIKV expression plasmids will be made available via Addgene.
A549-ZIKV-RNA, IVT-RNA, VERO-EMCV-RNA and
HEK293T-IAV-RNA
A549-ZIKV-RNA was generated by infection of A549 cells
with ZIKV (isolate ZIKV/H.sapiens/Brazil/PE243/2015, GenBank
accession KX197192.1, described in [34]) at an MOI of 5. Unless
indicated otherwise, cells were lysed in TRIzol (Invitrogen) 20 h
later and total RNA was extracted according to manufacturer’s
instructions. Neo1-99 in vitro transcribed RNA was generated as
previously described [31]. Purified RNAs were incubated with
alkaline phosphatase (Roche) using 2 units of enzyme per micro-
gram of RNA. Samples were incubated at 50°C for 1 h and RNAs
were purified by phenol-chloroform extraction. Negative control
reactions were performed in parallel by omitting the enzyme.
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VERO-EMCV-RNA was generated as described previously [32].
VERO EMCV-RNA (CIP) was created by treatment of purified
Vero EMCV-RNA with 2 units calf intestinal phosphatase (CIP)
(Roche) per μg of RNA for 1 h at 50°C and subsequent purification
by phenol-chloroform extraction. HEK293T-IAV-RNA was gener-
ated by infection of HEK293T cells with influenza A virus (IAV)
(A/PR/8/34 (H1N1), kind gift from Alain Townsend, Oxford, UK)
at an MOI of 5. Total RNA was extracted 24h later using TRIzol
according to manufacturer’s instructions.
Generation and validation of the p125-HEK reporter
cell line
Lentiviruses were produced in HEK293T cells (kind gift from Cae-
tano Reis e Sousa, The Francis Crick Institute, London, UK), using
Fugene6 (Promega) to transfect the p125-GreenFire plasmid in
combination with the Vira Power packaging mix (Invitrogen).
Medium was replaced the day after transfection. Supernatant was
collected 48 h post transfection and filtered through a 0.45 μm
PES filter. 1.5 × 106 HEK293 cells (kind gift from Caetano Reis e
Sousa, The Francis Crick Institute, London, UK) were subsequently
infected with 1 mL of viral supernatant in the presence of 8 μg/mL
of polybrene. The following day, the inoculum was removed and
fresh medium was added to the cells. One week later, cells were
cloned by limiting dilution. After 26 days, several clones were har-
vested from plates that had initially been seeded with less than 0.4
cells per well. These clones were expanded and tested by trans-
fection of IVT-RNA. Clone 17 was selected for having both, a high
amplitude of response and a high sensitivity.
Generation and validation of p125-HEK KO cell lines
using CRISPR technology
sgRNAs targeting RIG-I, MDA5 and MAVS were selected based on
the MIT algorithm (crispr.mit.edu). Specifically, the RIG-I sgRNA
targets exon 2, the MDA5 sgRNA exon 1, and the MAVS sgRNA
exon 5, which is the first common exon shared by the full-length
protein and Mini-MAVS [61]. All sgRNAs were cloned into a mod-
ified version of the pX458 plasmid (Addgene 48138, deposited by
Dr. Feng Zhang). We replaced the eGFP moiety of pX458 by inser-
tion of the mRuby2 cDNA and all sgRNAs were cloned using the
dual BbsI strategy and the incompatible CACC/AAAC overhangs
(oligos used for cloning are listed in Supporting Information Table
1). For RIG-I, an additional G was added at sgRNA position 0 to
reconstitute an optimum Pol-III promoter, whereas for MDA5 and
MAVS the original protospacers were cloned.
For the generation of the KO cell lines, p125-HEK clone 17
cells were seeded in a 6-well plate at 8.5 × 105 cells per well
one day before transfection with 5 μg of plasmid complexed with
5 μL of Lipofectamine LTX (Invitrogen) and 5 μL of Plus reagent
per well. The medium was replaced one day later. On the fol-
lowing day, cells were harvested and single Ruby-positive cells
were FACS-sorted into 96-wells. Clones were harvested 27 days
later.
In order to identify the mutations at the target loci, sgRNA
targeted p125-HEK cells were washed with PBS and re-suspended
in QuickExtract solution (Epicentre, catalogue # QE 09050). After
15 seconds of vortexing, lysates were incubated for 6 min at 65°C,
vortexed again, then incubated for 2 min at 98°C. 200ng of DNA
was used in a 50 μL PCR reaction using Phusion polymerase in
the presence of 3% of DMSO. PCR products were gel purified
with QIAquick Gel Extraction Kit and sequenced using the PCR
primers listed in Supporting Information Table 1. Sequences were
analyzed using the TIDE software (https://tide.nki.nl) [62].
To further validate the KO cell lines, cells were seeded into
either 24-well (WT, RIG-I KO and MAVS KO) or 6-well (WT and
MDA5 KO) plates. Once almost confluent, cells were either treated
with 140U/mL of IFN-A/D overnight before lysis in 1% NP-40 lysis
buffer (25 mM Tris-HCl pH7.4, 150 mM NaCl, 2 mM EDTA, 5%
glycerol, 1% NP-40, 1:100 Protease inhibitor cocktail) or infected
with Sendai virus at an MOI of 0.5 per well for 24 h, before lysis
in 0.5% NP-40 lysis buffer (20mM Tris-HCl pH7.4, 100 mM NaCl,
1 mM EDTA, 0.5% NP-40, 1:100 Protease inhibitor). Lysates were
incubated for 30 min on ice, then cellular debris was removed
by centrifugation and supernatants were used for SDS-PAGE and
blotting as described below.
p125-HEK cell stimulation
p125-HEK clone 17 cells were seeded at 50 000 cells per well in
a 96-well plate. On the following day, cells were transfected with
different doses of IVT-RNA or A549-ZIKV-RNA complexed with
0.2 μL of Lipofectamine per well. Activation of the IFNβ promoter
was assessed one day later by OneGlo luciferase assay (Promega).
RIG-I- and MDA5-KO p125-HEK cells were validated by stimu-
lation with IVT-RNA and VERO-EMCV-RNA (CIP), selective RIG-
I and MDA5 agonists, respectively (Supporting Information Fig.
1N). To validate that MAVS-KO p125-HEK cells can still activate
the IFNβ promoter, WT andMAVS-KO p125-HEK cells were seeded
at 20 000 cells per well in a 96-well plate. On the next day, cells
were treated with 200U/mL IFN-α. After 24 h, cells were trans-
fected with 100 ng of pcDNA3-MAVS. Luciferase activity was mea-
sured 1 day later.
FACS
We adhered to EJI guidelines for FACS. p125-HEK cells were
seeded at 200 000 cells per well in a 24-well plate 1 day before
transfection with graded doses of IVT-RNA complexed with 1 μL
of Lipofectamine. On the next day, cells were trypsinized, resus-
pended in FACS buffer (PBS, 1% FCS, 2mM EDTA, 0,02% sodium
azide) containing 1 μg/mL of DAPI and immediately analyzed
using a CyAn ADP High-Performance Flow Cytometer (DakoCy-
tomation). Cellular debris and doublets were gated out using For-
ward Scatter and Side Scatter Channels, and dead cells using DAPI
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staining (violet 1 channel). Between 27 000 and 30 000 live single
cells were analyzed per sample for GFP expression.
Antibodies
Primary antibodies utilized for immunoblotting were: STAT1
(clone 42H3, Cell Signaling, 1:1000), pSTAT1(Y701) (clone
D4A7, Cell Signaling, 1:1000), STAT2 (clone D9J7L, Cell Sig-
naling, 1:1000), RIG-I (clone Alme-1, AdipoGen, 1:1000), MAVS
(Enzo Life Sciences #ALX-210-929-C100, 1:500), MDA5 (clone
17, mouse monoclonal antibody raised in-house), V5-HRP (Invit-
rogen, 1:5000), beta-actin-HRP (clone AC-15, Sigma Aldrich, 1:10
000), GAPDH-HRP (Proteintech, 1:10 000) and FLAG-HRP (clone
M2, Sigma Aldrich, 1:10 000). HRP-coupled secondary antibodies
include sheep-α-mouse and donkey-α-rabbit (both GE Healthcare,
1:3000).
Western blot analysis
HEK293 or HEK293T cells were seeded at a density of 8 × 105
or 1 × 106 cells/well, respectively, in 6-well plates. 24 h later,
cells were transfected with 1500 ng of ZIKV or control plas-
mids using Lipofectamine 2000 (Invitrogen). Where indicated
cells were treated with recombinant human IFN-A/D on day three
(Sigma-Aldrich or R&D Systems). After an additional 24 h incu-
bation period, cells were lysed in lysis buffer (50 mM TRIS-HCl
pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium
deoxycholate) containing 1:100 Protease Inhibitor Cocktail (Cell
signaling Technology). Phosphatase Inhibitor Cocktail 3 (Sigma-
Aldrich) was added for analysis of STAT protein phosphoryla-
tion. Supernatants were removed after centrifugation. Protein con-
centrations were determined using Pierce BCA Protein Assay Kit
(Thermo Scientific) and equalized by dilution of samples with
lysis buffer. Subsequently, 5× Laemmli sample buffer (312.5mM
TRIS-HCl, 10% SDS, 25% beta-mercaptoethanol, 50% glycerol,
0.01% bromophenol blue, pH 6.8) was added and samples were
incubated at 95°C for 10 min. Samples were run on NuPAGE
Novex 4–12% Bis-TRIS gels (Invitrogen) using NuPage MOPS-
SDS running buffer (Invitrogen). Proteins were subsequently blot-
ted onto PROTRAN Pure nitrocellulose membrane (PerkinElmer).
Membranes were blocked with 5% skim milk powder (Sigma-
Aldrich) in TBS 0.1% Tween-20 (5% milk TBS-T) for 1 h at room
temperature and were then incubated with primary antibodies in
5% milk TBS-T overnight at 4°C. Primary antibodies that bind
to phosphorylated residues were diluted in 5% BSA in TBS-T.
Membranes were washed thrice with TBS-T and incubated with
HRP-coupled secondary antibodies in 5% milk TBS-T for 1 h at
room temperature. After three further washeswith TBS-T, proteins
were detected using Western LightningPlus-ECL (PerkinElmer)
and Amersham Hyperfilm MP (GE Healthcare). If needed, anti-
bodies were stripped from the membrane with stripping buffer
(200 mM glycine, 0.1% SDS, 1% Tween-20, pH 2.2) for 20 min at
room temperature. Membranes were washed with TBS-T, blocked
as previously and re-probed.
Luciferase assay
For luciferase assays, cells either stably transduced with F-Luc
reporter constructs (3C11, p125-HEK, p125-HEK-KOs) or tran-
siently transfected with F-Luc reporter and Renilla luciferase con-
trol plasmids were utilized. For stable cell lines, One-GLO reagent
and GLO-Max luminometer (both Promega) were used to mea-
sure F-Luc intensity. For cells transfected with firefly and Renilla
luciferase plasmids, Dual-Luciferase Assay System (Promega) was
used according to manufacturer’s instructions and F-Luc activity
was normalized to R-Luc activity.
RT-qPCR
A549 cells were infected with ZIKV (see above) at an MOI of
5 and total RNA was extracted after 4, 8, 24, 48 and 72 h
using TRIzol (Invitrogen) according to manufacturer’s instruc-
tions. RNA concentration was measured with a Nanodrop sys-
tem (Thermo Fischer Scientific). RNA was reverse transcribed
into cDNA using SuperScript II Reverse Transcriptase (Invitro-
gen). The PCR reaction containing TaqMan Universal PCR Master
Mix (Applied Biosystems) and TaqMan Primer/Probes (see below)
was run on 7500 Fast Real time PCR System (Applied Biosystems)
or QuantStudio 7 Flex Real-Time PCR System (Thermo Fischer
Scientific) with the following cycle conditions: 10 min 95°C, and
40 cycles of 15 s 95°C followed by 1 min 60°C. Gene expression
was analyzed with the Ct method using GAPDH expression for
normalization.
HEK293T cells were seeded at a density of 1.5 × 105 cells/well
in 24 well plates. 24 h later, cells were transfected with 300 ng of
ZIKV or control plasmids using Lipofectamine 3000 (Invitrogen).
On day three of the experiment, cells were treated with recombi-
nant IFN-A/D. After an additional 24-h incubation period, RNA
was extracted from cells using the QIAshredder (Qiagen) and
RNeasy Mini Kit (Qiagen) according to manufacturer’s instruc-
tions. RNA was used for RT-qPCR as described above.
TaqMan primer probes used include GAPDH (Assay ID:
Hs02758991 g1), DDX58 (RIG-I) (Assay ID: Hs01061436 m1),
IFIT1 (Assay ID: Hs03027069 s1), MX1 (Assay ID:
Hs00895608 m1), IFI44 (Assay ID: Hs00951349 m1) and
IFNB1 (Assay ID: Hs02621180 s1).
Microscopy
NS5-eYFP was excited with a 488 nm laser and the emission
was collected between 520 and 570 nm. For visualization of
cellular localization of NS5 NLS mutants in living cells, nuclei





Reagent (Thermo Fisher). For FRAP analysis, 1%
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laser power (100 μW) was used for imaging. A circular region
of interest (ROI) was bleached using 75% of the laser power (10
mW). 100 frames were recorded after the bleaching with no time
interval between the frames. A recovery curve was generated using
the Stack T-Function - Intensity vs. TimeMonitor plugin of ImageJ.
A Zeiss 880 confocal microscope was used in all experiments.
RIG-I pulldowns
For investigation of RIG-I bound RNA, 1.25μg recombinant FLAG-
RIG-I protein [16] and 5 μg infected cell total RNA (see above)
were incubated under rotation at 4°C for 1 h in 250 μL IP buffer
(20 mM TRIS-HCl pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.5% NP-
40, 0.05 U/mL RNasin Plus RNase inhibitor (Promega)). Where
indicated, RIG-I protein was denatured by heating to 95°C for 10
min prior to mixing with RNA. As input samples, 5 and 40 μL were
removed for Western Blot analysis and RNA extraction, respec-
tively. Samples were rotated as previously with 4 μg α-FLAG anti-
body (clone M2, Sigma-Aldrich) or mIgG1 isotype control anti-
body (clone MOPC-31C, BD Pharmingen) for 2 h. Samples were
added to 50 μl Protein G Dynabeads (Invitrogen) and rotated
again for 2 h. Beads were separated from supernatant and 5 and
40μL were removed from supernatant as unbound samples. Beads
were resuspended in IP buffer and split 10–90% for Western Blot
and RNA extraction, respectively.
For Western blotting, 4× Laemmli sample buffer (200 mM
TRIS-HCl, 8% SDS, 20% beta-mercaptoethanol, 40% glycerol,
0.01% bromophenol blue, pH 6.8) was added to input, unbound
and bound fractions and samples were incubated at 95°C for 10
min. Beads were removed and samples were subjected to SDS-
PAGE and blotting as described above.
TRIzol was added to input, unbound and bound fractions and
RNA was extracted according to manufacturer’s instructions. RNA
was resuspended in 20 μL water. For luciferase assay, p125HEK
reporter cells were seeded at 2.5× 104 cells/well in 96 well plates,
transfectedwith 1μL of RNA samples per well using Lipofectamine
2000 and assayed as described above. For RT-qPCR, 4 μL of RNA
samples were reverse transcribed into cDNA using SuperScript II
Reverse Transcriptase (Invitrogen) in a 20 μL reaction. The 10 μL
PCR reaction containing 1μL cDNA, EXPRESS SYBRTM GreenERTM
qPCR Supermix (Invitrogen) and 10 μM primers (see Supporting
Information Table 1) was run on QuantStudio 7 Flex Real-Time
PCR System (Thermo Fischer Scientific) with the following cycle
conditions: 10 min 95°C, and 40 cycles of 15 s 95°C followed by 1
min 60°C, and melt curve analysis. Abundance was analyzed with
the Ct method and expressed as 2−Ct.
Data analysis and statistics
Primary data were analyzed using Office Excel 2016 (Microsoft)
and GraphPad Prism v7.00 (GraphPad Software). SnapGene (GSL
Biotech) and ApE (M. Wayne Davis, The University of Utah) were
utilized to assist cloning. The TIDE algorithm was used to analyze
KO clone sequences [62]. Quantitative analysis of Western blots
was performed using ImageJ [63]. Graphs and figures were cre-
ated using GraphPad Prism v7.00 and Adobe Illustrator (Adobe
Systems). Statistical analysis was performed in GraphPad Prism
v7.00 as detailed in the Figure legends.
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